Insulin glargine (Basaglar) vs Insulin sudelidec (INS068)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline
Insulin glargine (Basaglar)
Marketed by Eli Lilly and partners
NCT01421459 · Phase 3 · completed
The study was randomized, triple-blind, and active-controlled, with 759 participants, but its primary endpoint was HbA1c, a laboratory surrogate rather than a hard clinical outcome. The prespecified non-inferiority comparison was met: the 95% confidence interval for the treatment difference remained below the +0.4% margin.
Reported efficacy
Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062) (met)
Result source: NCT03338010
Insulin sudelidec (INS068)
Marketed by Jiangsu Hengrui Pharmaceuticals
NCT05699408 · Phase 3 · completed
This Phase 3 trial randomly assigned 513 people with type 2 diabetes to insulin sudelidec or to insulin glargine, alongside their existing oral diabetes medicines. It was open-label, so treatment assignment was known throughout. HbA1c fell by 1.34 percentage points on insulin sudelidec against 1.37 on insulin glargine, a difference of 0.02 points (95% CI -0.14 to 0.18), meeting the prespecified test that it was not worse than glargine.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Reported efficacy
Change in HbA1c (Week 0 to Week 26): Change in HbA1c at Week 26 (Study 302, oral-antidiabetic-drug background, n=513): insulin sudelidec (INS068) -1.34% vs insulin glargine -1.37%; between-group difference 0.02% (95% CI -0.14% to 0.18%) (met)
Result source: NCT05699408
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Insulin glargine (Basaglar) | Insulin sudelidec (INS068) |
|---|---|---|
| HbA1c, change | -1.3% vs -1.3%vs LantusNCT014214599 other results
| -1.3% vs -1.4%avs insulin glargineNCT05699408 |
| Body weight, change (kg) | 1.9 vs 2.2vs LantusNCT014214597 other results
| —Not posted · NCT05699408 |
| HbA1c below 7% | 43.7% vs 44.9%vs Lantus®NCT03338010 | —Not posted · NCT05699408 |
| Fasting plasma glucose, change | —Not reported | —Not posted · NCT05699408 |
| 3-point MACE (% with event) | —Not reported | —Not posted · NCT05699408 |
HbA1c, change
- Insulin glargine (Basaglar)
- -1.3% vs -1.3%vs LantusNCT01421459
9 other results
- -1.3% vs -1.2% NCT02302716
- -1.3% vs -1.2% NCT03338010
- -1.3% vs -1.4% NCT01421459
- -1.3% vs -1.2% NCT03338010
- -1.3% vs -1.4% NCT01421459
- -1.3% vs -1.3% NCT01421459
- -1.1% vs -1.1% NCT01421459
- -0.9% vs -0.9% NCT01421459
- -0.5% vs -0.5% NCT01421459
- Insulin sudelidec (INS068)
- -1.3% vs -1.4%avs insulin glargineNCT05699408
Body weight, change (kg)
- Insulin glargine (Basaglar)
- 1.9 vs 2.2vs LantusNCT01421459
7 other results
- 2.3 vs 1.7 NCT02302716
- 1.1 vs 1.2 NCT03338010
- 1.7 vs 2.2 NCT01421459
- 1.6 vs 1.9 NCT01421459
- 1.3 vs 1.4 NCT01421459
- 1.0 vs 1.2 NCT01421459
- 0.3 vs 0.5 NCT01421459
- Insulin sudelidec (INS068)
- —Not posted · NCT05699408
HbA1c below 7%
- Insulin glargine (Basaglar)
- 43.7% vs 44.9%vs Lantus®NCT03338010
- Insulin sudelidec (INS068)
- —Not posted · NCT05699408
Fasting plasma glucose, change
- Insulin glargine (Basaglar)
- —Not reported
- Insulin sudelidec (INS068)
- —Not posted · NCT05699408
3-point MACE (% with event)
- Insulin glargine (Basaglar)
- —Not reported
- Insulin sudelidec (INS068)
- —Not posted · NCT05699408
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Insulin glargine (Basaglar): 4 of 4 rows · Insulin sudelidec (INS068): 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Insulin glargine (Basaglar) | Insulin sudelidec (INS068) |
|---|---|---|
| Dropout rate | 11.9%a NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 3 more results7.6% NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3 6.4% NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 28.3% NCT04153981 · Phase 4 · registry result, not featured evidence | — |
| Discontinued due to AEs | 1.6%a NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 3 more results0.4% NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.8% NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 — NCT04153981 · Phase 4 · registry result, not featured evidence | — |
| Serious AEs | 4%a NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 3 more results4% NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.8% NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 0.4% NCT04153981 · Phase 4 · registry result, not featured evidence | — |
| Most frequent reported AEs | a nasopharyngitis 5.6% upper respiratory tract infection 5.1% abnormal weight gain 2.7% NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 3 more resultsnasopharyngitis 7.2% upper respiratory tract infection 4% weight increased 3.2% NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3 upper respiratory tract infection 20.3% hypertension 5.6% injection site pain 4.2% NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 anaemia 1.9% cough 0.4% hyperglycaemia 0.4% NCT04153981 · Phase 4 · registry result, not featured evidence | — |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Insulin glargine (Basaglar)
show 7 more results
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin glargine (Basaglar)'s landscape · Insulin sudelidec (INS068)'s landscape